Ipilimumab retreatment following induction therapy: The expanded access program (EAP) experience

被引：0
|
作者：
Margolin, Kim Allyson
Hamid, Omid
Weber, Jeffrey S.
Pavlick, Anna C.
Hodi, F. Stephen
Amin, Asim
Bennett, Kelly
Michener, Tracy
Minor, David R.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Angeles Clin & Res Inst, Los Angeles, CA USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Comprehens Melanoma Res Ctr, Tampa, FL USA
[4] NYU, Dept Med, Langone Med Ctr, New York, NY 10016 USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Levine Canc Inst, Charlotte, NC USA
[7] Bristol Myers Squibb, Plainsboro, NJ USA
[8] Calif Pacific Ctr Melanoma Res & Treatment, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9041
引用
收藏
页数：1
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY OF IPILIMUMAB IN PATIENTS WITH PRETREATED, OCULAR MELANOMA: EXPERIENCE FROM ITALIAN CLINICS PARTICIPATING IN THE EUROPEAN EXPANDED ACCESS PROGRAMME (EAP)
    Maio, M.
    Sileni, V. Chairion
    Pilla, L.
    Nicoletti, S. V. L.
    Di Guardo, L.
    Queirolo, P.
    De Galitiis, F.
    Mandala, M.
    Guida, M.
    Ascierto, P. A.
    ANNALS OF ONCOLOGY, 2012, 23 : 369 - 370
  • [32] EFFICACY AND SAFETY OF IPILIMUMAB IN PATIENTS WITH PRETREATED, MUCOSAL MELANOMA: EXPERIENCE FROM ITALIAN CLINICS PARTICIPATING IN THE EUROPEAN EXPANDED ACCESS PROGRAMME (EAP)
    Del Vecchio, M.
    Simeone, E.
    Sileni, V. Chiarion
    Nuzzo, C.
    Rinaldi, G.
    Testori, A.
    De Galitiis, F.
    Queirolo, P.
    Marconcini, R.
    Maio, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 368 - 368
  • [33] Overall survival and safety experience from an expanded access program (EAP) of nivolumab (NIVO) for patients with advanced melanoma (MEL) who progressed after prior ipilimumab (IPI) treatment
    Barros e Silva, Milton
    Schmerling, Rafael
    de Melo, Andreia Cristina
    Azevedo, Sergio
    Garicochea, Bernardo
    McWhirter, Elaine
    Smylie, Michael
    Gifoni, Markus
    dos Anjos, Carlos Henrique
    Petrella, Teresa
    Chacon, Matias
    Greco, Martin
    Nair, Suresh
    Avila, Alexandre
    Demelo, Sheena
    Jiang, Joel
    Ernst, Scott
    CANCER RESEARCH, 2017, 77
  • [34] Efficacy of nivolumab and ipilimumab (Nivo plus Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP).
    Shoushtari, Alexander Noor
    Navid-Azarbaijani, Pedram
    Friedman, Claire Frances
    Panageas, Katherine
    Postow, Michael Andrew
    Callahan, Margaret K.
    Momtaz, Parisa
    Campbell, Shonnette C.
    Shames, Yelena
    Prempeh-Keteku, Nana A.
    Nwaedozie, Kasiemobi
    Wolchok, Jedd D.
    Chapman, Paul B.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] Expanded access protocol (EAP) program for access to investigational products for amyotrophic lateral sclerosis (ALS)
    Yerton, Megan
    Winter, Allison
    Gelevski, Dario
    Addy, Grace
    Kostov, Anthony
    Lieberman, Cassandra
    Weber, Harli
    Doyle, Michael
    Kane, Geli
    Cohen, Caroline
    Parikh, Neil
    Burke, Katherine M.
    Rohrer, Margot
    Stirrat, Taylor
    Bruno, Margaret
    Hochman, Alison
    Luppino, Sarah
    Scalia, Jennifer
    D'Agostino, Derek
    Sinani, Ervin
    Yu, Hong
    Drake, Kristin
    Hagar, Jennifer
    Sherman, Alexander V.
    Babu, Suma
    Berry, James D.
    Cudkowicz, Merit E.
    Paganoni, Sabrina
    MUSCLE & NERVE, 2023, 67 (06) : 456 - 463
  • [36] Toxicity associated with ipilimumab and nivolumab (Ipi plus Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP).
    Friedman, Claire Frances
    Navid-Azarbaijani, Pedram
    Shoushtari, Alexander Noor
    Campbell, Shonnette C.
    Callahan, Margaret K.
    Momtaz, Parisa
    Prempeh-Keteku, Nana A.
    Postow, Michael Andrew
    Shames, Yelena
    Wolchok, Jedd D.
    Chapman, Paul B.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] Treatment duration of brigatinib in patients enrolled in the international expanded access program (EAP)
    Lin, M. M.
    Pan, X.
    Hou, P.
    Allen, S.
    Baumann, P.
    Hochmair, M. J.
    ANNALS OF ONCOLOGY, 2019, 30 : 42 - 42
  • [38] Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results
    Hamid, Omid
    Hwu, Wen-Jen
    Richards, Jon M.
    Weber, Jeffrey S.
    Wolchok, Jedd D.
    Sznol, Mario
    Minor, David R.
    Pavlick, Anna C.
    Urba, Walter John
    Hodi, F. Stephen
    Yang, Arvin
    Michener, Tracy
    Balogh, Agnes
    McDermott, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] Safety and efficacy of ABT 378/r in the German expanded access program (EAP)
    Voigt, E
    Wasmuth, JC
    Braitinger, D
    Kupfer, B
    Kaiser, R
    Rockstroh, JK
    AIDS, 2000, 14 : S29 - S30
  • [40] Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).
    Hogg, David
    Chapman, Paul B.
    Sznol, Mario
    Lao, Christopher D.
    Gonzalez, Rene
    Daniels, Gregory A.
    Smylie, Michael
    Kudchadkar, Ragini Reiney
    Thompson, John A.
    Sharfman, William Howard
    Atkins, Michael B.
    Pavlick, Anna C.
    Jiang, Joel
    Avila, Alexandre
    Demelo, Sheena
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345